Overview

Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil

Status:
Completed
Trial end date:
2017-11-09
Target enrollment:
Participant gender:
Summary
This is an 8-week, randomized, placebo-controlled trial of modafinil in stable bipolar disorder patients. Results will provide information on a promising treatment for simultaneously treating both sleep and cognitive problems in stable bipolar patients. These disabling symptoms persist despite stable mood and are strongly associated with functional disability, making them important treatment targets that have not yet been adequately addressed.
Phase:
Phase 4
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Armodafinil
Modafinil